Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.

Inclusion criteria

• Have been receiving liver transplant two years ago.
• Be 18 years or older.
• Treatment with immunosuppression including cyclosporine or tacrolimus.
• Having a normal liver function in the last year
• Not have suffered acute rejection in the last year and have no chronic rejection
• Submit any significant side effects from medication immunosuppressive (hypertension, creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis, hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.)
• Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma, metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or autoimmune.
• Patients offering sufficient guarantees of adherence to protocol
• Patients who give written informed consent for participate in the study.
• It is necessary that the patient meets all inclusion criteria.

Exclusion criteria

• Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or autoimmune.
• Patients with chronic rejection, or acute rejection in the last year.
• Patients with liver retransplantation.
• patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen, psoralen the compounds or any of the excipients.
• patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent.
• Patients with aphakia.
• Patients taking Oxoralen.
• Pregnant women or nursing mothers, or adults of childbearing age not using effective contraception.
• Participation in another clinical trial.
• Inability to understand informed consent.